Search clinical trials for: Comparator: raltegravir

Total 2233 results

Clinical Nutrition Research Center, Illinois Institute...

Completed

Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance (GSE3)

Impaired Glucose Tolerance

United States
Merck Sharp & Dohme LLC

Completed

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

Human Immunodeficiency Virus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

HIV Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

HIV Infections
Merck Sharp & Dohme LLC

Terminated

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

HIV Infection
Merck Sharp & Dohme LLC

Terminated

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)

HIV Infection
Merck Sharp & Dohme LLC

Terminated

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

HIV
Kirby Institute

Completed

Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response (CORAL)

HIV Infections
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) (onceMRK)

HIV Infection
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

HIV Infections

United States, Puerto Rico, South Africa, Argentina, Brazil, Botswana
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

HIV | Neurotoxicity | HIV-associated Neurocognitive Disorder

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

HIV Infections
ViiV Healthcare

Completed

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
Merck Sharp & Dohme LLC

Completed

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) (RACING)

HIV Infections
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
Eisai Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Alzheimer's Disease

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
Merck Sharp & Dohme LLC

Withdrawn

A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Breast Cancer
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
ANRS, Emerging Infectious Diseases

Completed

Evaluation of Raltegravir During the Third Trimester of Pregnancy (ANRS 160 RalFE)

HIV-1 Infection | PREGNANCY

France
Merck Sharp & Dohme LLC

Terminated

The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

Middle Cerebral Artery Stroke
TiumBio Co., Ltd.

Recruiting

TUC3PII-01_TU2670 Phase IIa Clinical Study

Endometriosis

Czechia, Italy, Russian Federation, Poland, Ukraine
Merck Sharp & Dohme LLC

Terminated

A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)

Type 2 Diabetes
Cognition Therapeutics

Recruiting

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Age-Related Macular Degeneration

United States
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)

Sarcopenia
IrsiCaixa

Completed

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

HIV-1 Infection

Spain
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Completed

DDI HV (ATV - Merck)

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

Healthy
Merck Sharp & Dohme LLC

Completed

Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)

Rotavirus
United States Naval Medical Center, San Diego

Terminated

Low -vs- High-Frequency Repetitive TMS of the Right Dorsolateral Prefrontal Cortex in PTSD

PTSD - Post Traumatic Stress Disorder
Guangzhou JOYO Pharma Co., Ltd

Recruiting

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

China
AbbVie

Withdrawn

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Psoriasis
Clinical Nutrition Research Center, Illinois Institute...

Completed

Acute Effects of Coffee Beverage on Postprandial Inflammation and Oxidative Stress - A Pilot Study (COF1)

Healthy | Overweight | Obese

United States
St Stephens Aids Trust

Completed

Raltegravir and Ezetimibe PK Study

HIV

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers

Osteoporosis
Merck Sharp & Dohme LLC

Completed

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Neoplasms, Glandular and Epithelial | Whooping Cough | Tetanus | Diphtheria | Meningitis
Universidad Peruana Cayetano Heredia
Merck Sharp & Dohme LLC

Completed

Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

HTLV-I Infections | Tropical Spastic Paraparesis

Peru
Merck Sharp & Dohme LLC
Covance

Completed

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

HIV Infection
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB

HIV Infections | Tuberculosis

South Africa
Arbeitsgemeinschaft medikamentoese Tumortherapie
Merck Sharp & Dohme LLC

Completed

Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

HIV Infections

Austria
Shanghai Public Health Clinical Center

Unknown

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

HIV

China
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin. (AVIATOR)

HIV | Hypercholesterolaemia

Netherlands
Merck Sharp & Dohme LLC

Completed

Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)

Hepatitis B
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)

Healthy
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Stanford University

Recruiting

Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder

Treatment Resistant Depression | Bipolar II Disorder, Most Recent Episode Major Depressive | Current Depressive Episode

United States
University of Palermo

Completed

Gluten-related Disorders in Familial Mediterranean Fever Patients

Familial Mediterranean Fever (FMF) | Not-celiac Wheat Sensitivity (NCWS)

Italy
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)

Healthy

3

Subscribe